Cortechs.ai | Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant<sup>®</sup>

Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant®

Cortechs.ai expands market reach into Canada for NeuroQuant, the leading volumetric brain imaging solution for MRIs.

(SAN DIEGO) Feb. 2, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that it has received Health Canada/Santé Canada Medical Device License for marketing and distribution of NeuroQuant® in Canada. Already FDA cleared and CE marked, NeuroQuant is used throughout the world by physicians in hundreds of reputable clinics and hospitals to help in their assessment of neurodegeneration.

Fully automated, NeuroQuant provides neurologists, radiologists, and clinical researchers with an accurate and convenient tool to quantify the volumes of specific brain structures in order to better assess neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

“The Heath Canada/Santé Canada Medical Device License is a testament to our commitment to quality, safety and performance and now allows customers in Canada to start using NeuroQuant in their clinical practice,” commented Guri Stark, CEO of Cortechs.ai. “We are excited to introduce our innovative brain imaging solution to Canadian hospitals, clinics and universities and expand access to proven and reliable quantitative volumetric analysis of neurological conditions via MR imaging.”

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of MRI images of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top